Across TCGA pan-cancer cohorts, ANKRD34A mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ANKRD34A data layer compared with 23 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher ANKRD34A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ANKRD34A expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.
GBM are the cancer types where ANKRD34A mass-spec protein most reproducibly stratifies survival.